OmniAb Inc reports results for the quarter ended March 31 - Earnings Summary

• OmniAb Inc OABI.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -19 cents. The mean expectation of eight analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -18 cents to -15 cents per share.

• Revenue rose 9.3% to $4.15 million from a year ago; analysts expected $4.49 million.

• OmniAb Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $18.2 million.

• OmniAb Inc shares had fallen by 36.2% this quarter and lost 56.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for OmniAb Inc is $8.00

This summary was machine generated from LSEG data May 8 at 10:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)